United States Patent 12,290,651: Scope, Claims, and Patent Landscape
US Drug Patent 12,290,651 claims an applicator device for topical dispensing that combines (1) a tube-ampule-fluid system, (2) a tapered dispensing tip with droplet control, (3) a drip guard with trough and external grooves, (4) an optional taper-tip filter that blocks ampule shard particles ≥150 µm, (5) cap-based venting control, and (6) a specific solvent and formulation window tied to actives that include cantharidin.
The claim set is structured so the core device elements read broadly across many topical solvent-actives, while the most constrained coverage appears in the filter/shard-blocking, cap venting only through defined routes, and composition formulation percentages.
What does claim 1 cover (the “device core”)?
Claim 1 establishes the baseline: an applicator device with these required parts and configuration features:
Mandatory structural elements
- Tube
- Ampule positioned within the tube
- Pharmaceutical composition contained within the ampule
- Dispenser tip attached to the tube
- Dispenser tip has:
- Tapered tip
- Drip guard with:
- Trough configured to receive fluid running down the outer surface of the tapered tip
- One or more grooves formed on an external side of the drip guard
Functional focus
- The drip guard defines a path and containment mechanism for liquid on the outside of the tapered tip.
- The external grooves on the drip guard are a structural limitation tied to the device’s fluid management.
Practical reading for scope: any product that uses a tube-retained ampule and a tapered dispensing tip with an outer drip guard trough plus external grooves can fall within claim 1 even if the internal formulation differs, unless later dependent claims narrow.
Where does the claim scope narrow materially (device sub-features)?
1) Optional filter for shard inhibition (claim 2 + 3)
Claim 2 adds:
- A filter positioned within the tapered tip
- Filter “constructed and arranged” to:
- permit passage of fluid
- inhibit passage of broken ampule shards having particle size ≥150 µm
Claim 3 further narrows:
- Filter is held via an interference fit between:
- the filter
- and the inner surface of the tapered tip
Materiality: this is a discrete engineering limitation that can be designed around by:
- altering shard generation,
- using different retainer structures,
- changing particle-size filtration threshold,
- placing filtration elsewhere (unless the literal position is met: “within the tapered tip”).
2) Defined droplet dispensing (claim 4)
Claim 4 requires:
- The tapered tip is configured to dispense discrete droplets.
This excludes or narrows devices that dispense continuously or as a stream.
3) Dual-angle taper geometry (claims 5 and 6)
Claim 5 requires:
- Dispenser tip has:
- an inner surface with at least a portion tapered at first taper angle
- an outer surface with at least a portion tapered at second taper angle
Claim 6 requires:
- Second taper angle differs from first.
This is a geometry-specific limitation and can reduce infringement risk for tips with single-taper designs.
4) Two-part internal diameter arrangement (claim 7)
Claim 7 requires:
- Dispenser tip has:
- first portion with tapering inner diameter
- second portion with constant inner diameter
5) Distal opening size (claim 8)
Claim 8 requires the tapered tip ends in:
- distal opening internal diameter <0.02 inches
- external diameter <0.05 inches
This is a quantifiable size window.
6) Cap-based venting limitation (claims 9–12)
Claim 9 adds:
- A cap with opening to receive dispenser tip
- Cap has:
- a closed position where at least a portion of the dispenser tip passes through the opening
- Cap is coupled to dispenser tip and positioned over at least part of dispenser tip
Claim 10 adds:
- When cap is closed, venting is permitted through the cap opening.
Claim 11 tightens:
- Venting occurs only through the opening of the cap.
Claim 12 further tightens:
- Venting permitted through cap opening at locations adjacent the one or more grooves on the external side of the drip guard.
Materiality: this is the highest-risk design-around area for competitors. A competitor can avoid literal scope by venting elsewhere, by removing groove adjacency, or by decoupling venting ports from the drip-guard groove locations.
7) Fluid-tight seal to tube (claim 13)
Claim 13 requires:
- At least part of dispenser tip attached to tube to form a fluid-tight seal between dispenser tip and tube.
8) Vacuum generation by squeeze-release (claim 14)
Claim 14 requires:
- Device creates a vacuum inside the tube when tube is squeezed and then released.
This limitation targets actuation mechanics and can be avoided by different fluid displacement methods.
What does claim 15 do for drug/formulation scope?
Claim 15 expands the pharmaceutical composition scope by listing compounds selected from:
- cantharidin
- antifungals
- antibacterials
- antivirals
- corticosteroids
- steroids
- immunostimulants
- chemotherapeutics
- keratolytics
- antihistamines
- anti-inflammatory agents
This dependent claim is broad on actives. It allows coverage beyond cantharidin if formulation is used in the claimed device.
How constrained is the cantharidin formulation (claims 16–19)?
Claim 16: base solvent and additive window (composition-level dependency)
Claim 16 specifies the composition comprises:
- cantharidin
- acetone
- ethanol
- a plasticizer
- a film-forming agent
Claim 17: additional excipient set
Claim 17 adds:
- hydroxypropylcellulose
- nitrocellulose
- castor oil
- camphor
- denatonium benzoate
- gentian violet
Claims 18–19: ether dependency
- Claim 18 adds: composition further comprises ether
- Claim 19 states composition is ether-free
These two create competing sub-scope branches: ether present vs ether absent.
How constrained is claim 20 (the full formulation numeric window)?
Claim 20 adds an extended composition formulation window with explicit wt/wt ranges:
Solvents
- Ethanol: ≥25 and ≤35 wt%
- Acetone: ≥55 and ≤65 wt%
- Ether: ≤10 wt%
Polymer and film components / functional excipients
- Hydroxypropylcellulose: ≥0.1 and ≤2 wt%
- Nitrocellulose: ≥2.0 and ≤10 wt%
- Castor oil: ≥0.5 and ≤2 wt%
Active and markers
- Cantharidin: ≥0.1 and ≤1.5 wt%
- Denatonium benzoate: ≥0.001 and ≤0.01 wt%
- Gentian violet: ≥0.0001 and ≤0.001 wt%
Scope reading
Claim 20 is the most narrow coverage: it requires the full device of claim 1 plus the defined composition percentage bands and identified ingredients.
Competitors can reduce infringement by:
- shifting solvent composition outside the ranges,
- omitting one of the marker ingredients (denatonium benzoate, gentian violet),
- moving polymer percentages outside bands,
- or using a different active system not meeting cantharidin concentration requirements (unless they rely on coverage under claim 15’s broader active universe).
Claim coverage map (what is broad vs what is narrow)
| Claim |
What is required (high-level) |
Scope character |
| 1 |
Tube + internal ampule + tapered dispenser tip + drip guard trough + external grooves |
Broadest device claim |
| 2 |
Adds filter in tapered tip blocking shards ≥150 µm |
Narrow engineering feature |
| 3 |
Filter held by interference fit |
Narrows further |
| 4 |
Tip dispenses discrete droplets |
Narrow functional limitation |
| 5–6 |
Dual taper angles (inner vs outer) with different angles |
Geometry-specific narrow |
| 7 |
Two-part inner diameter (taper then constant) |
Geometry-specific narrow |
| 8 |
Distal opening size limits (<0.02 in ID, <0.05 in OD) |
Quantitative narrow |
| 9–12 |
Cap coupled, closed position venting only via opening, venting adjacent to drip-guard grooves |
Vent-path and adjacency narrows |
| 13 |
Fluid-tight seal between dispenser tip and tube |
Mechanical limitation |
| 14 |
Vacuum created by squeeze-release in tube |
Actuation mechanics limitation |
| 15 |
Active class selection including cantharidin and other therapeutic classes |
Broad on actives |
| 16–19 |
Cantharidin + specific core solvent/plasticizer/film former; optional ether vs ether-free |
Medium to narrow formulation |
| 20 |
Full numeric formulation wt% ranges and listed excipients |
Narrowest (product-specific) |
How the “drip guard + grooves” language affects infringement risk
The drip guard limitation in claim 1 is:
- trough receiving fluid running down outer surface of tapered tip
- grooves formed on external side of drip guard
This creates two infringement tests:
- Does the device include a drip guard with a trough for captured fluid?
- Does it have one or more grooves on the external side?
If a competitor uses a drip guard but routes fluid without grooves, or grooves on an internal side, literal claim 1 may not read.
The cap venting limitation in claims 10–12 further ties venting locations to those same grooves:
- venting only through cap opening
- venting at locations adjacent the grooves
That linkage increases the design specificity requirement.
Patent landscape: what likely sits around this family (device + formulation)
The provided record contains only the US claim text you supplied. No publication number, assignee, priority data, CPC/USPC class, family members, examiner citations, or prosecution history is included. Without that, a full landscape mapping (competitor patents, filing dates, priority chains, and claim chart comparisons) cannot be produced without fabricating sources.
What can be done from the claim language alone is a structural landscape characterization: this patent sits at the intersection of three claim clusters that tend to map to distinct prior-art buckets in US practice.
Landscape bucket A: Topical applicators with tube-ampule systems
This relates to packaging and delivery mechanics:
- tube containing an internal breakable ampule
- squeezable actuation
- dispensing at a tapered outlet
- optional shard filtration
Prior art in this bucket usually comes from:
- wound care topical droplet applicators
- dermatology solvent-based film-forming topical delivery devices
- multi-component packaging systems with ampule breakage
Landscape bucket B: Drip guards, venting control, and aerosol/drop management
The claim uses:
- tapered tip
- drip guard trough
- external grooves
- cap venting only through cap opening
- venting adjacency to grooves
Prior art commonly includes:
- nail/cosmetic droplet applicators with anti-drip features
- syringe/needleless applicators with controlled vent pathways
- valve and cap systems that manage trapped air and dripping
Landscape bucket C: Cantharidin solvent systems and film-forming formulations
Claims 16–20 align with:
- cantharidin topical compositions
- solvent blends (acetone/ethanol)
- film formers and polymers (nitrocellulose, hydroxypropylcellulose)
- excipients that discourage misuse (denatonium benzoate) and provide tint (gentian violet)
Prior art in this bucket clusters around:
- cantharidin formulations for dermatologic use
- solvent balance and film formation
- excipient selection for stability, viscosity, and appearance
How competitors would design around (actionable claim weak points)
Based on literal limitations, the main design-around levers are:
-
Remove or change the drip-guard groove feature
- claim 1 requires external grooves on drip guard
- claim 12 ties venting adjacent to those grooves
-
Alter venting architecture
- claim 11 requires venting only through the cap opening
- claim 12 requires venting adjacent to drip-guard grooves
-
Avoid the “filter within tapered tip” shard-blocking
- claim 2 requires filter within tapered tip blocking particles ≥150 µm
- claim 3 requires interference fit
-
Change distal opening size and/or taper geometry
- claim 8 enforces strict dimensional limits
- claims 5–7 enforce specific taper angle and diameter profiles
-
Change actuation mechanics
- claim 14 requires vacuum created by squeeze-release
-
Move formulation outside numeric windows
- claim 20 is a tight wt% range package
- removing one specified ingredient (denatonium benzoate or gentian violet) breaks literal read of claim 20
- altering solvent percentages out of range breaks literal read of claim 20
Key Takeaways
- Claim 1 defines the core product: tube + internal ampule + tapered tip + drip guard trough + external drip-guard grooves.
- Claims 2–3 add a defensible engineering feature: a filter located in the tapered tip that inhibits ampule shard particles ≥150 µm, held by an interference fit.
- Claims 9–12 create a high-specificity venting strategy: cap-coupled closed position with venting only through the cap opening, and venting positioned adjacent to the drip-guard grooves.
- Claims 16–19 and 20 lock in formulation scope: from cantharidin solvent/film-former systems to a fully enumerated wt% window in claim 20.
- A competitor’s highest-value design-around targets are the drip-guard grooves, cap vent path, taper-tip filtration, and claim 20 solvent/excipient wt% ranges.
FAQs
1) Is claim 1 device-only or also tied to specific drug formulation?
Claim 1 requires a “pharmaceutical composition” in the ampule but does not specify numeric wt% or required ingredients. Those constraints appear in later dependent claims.
2) What is the most important limitation for preventing shard release?
The filtration limitation in claim 2: a filter within the tapered tip that inhibits broken ampule shard passage with particle size ≥150 µm.
3) Which claims most directly constrain the venting design?
Claims 10–12, especially claim 11 (“venting occurs only through the opening of the cap”) and claim 12 (venting adjacent the drip-guard grooves).
4) Which claim is the narrowest on composition?
Claim 20, because it requires a detailed wt% composition band for ethanol, acetone, optional ether ceiling, polymers, excipients, and defined cantharidin, plus denatonium benzoate and gentian violet bands.
5) Can an ether-containing formulation fall under the same patent scope?
Yes, depending on which dependent claim structure applies: claim 18 adds ether, while claim 19 requires ether-free. Products are typically evaluated against each dependent claim’s specific requirement.
References
[1] United States Patent 12,290,651 (claim text provided by user).
